Jauslin, Petra
Kulkarni, Pooja
Li, Hanbin
Vatakuti, Suresh
Hussain, Azher
Wenning, Larissa
Kerbusch, Thomas
Clinical trials referenced in this document:
Documents that mention this clinical trial
AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis
https://doi.org/10.1136/annrheumdis-2018-eular.2983
Old and new treatment targets in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2015-000054
Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis
https://doi.org/10.1007/s40262-019-00743-7
THU0291 Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate to severe plaque psoriasis: data from 3 large randomised clinical trials
https://doi.org/10.1136/annrheumdis-2018-eular.6782
SAT0312 Incidence of infections in clinical trials of tildrakizumab for moderate to severe chronic plaque psoriasis
https://doi.org/10.1136/annrheumdis-2018-eular.6730
AB0903 Efficacy of tildrakizumab in etanercept partial or nonresponders
https://doi.org/10.1136/annrheumdis-2018-eular.6758
Documents that mention this clinical trial
Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis
https://doi.org/10.1007/s40262-019-00743-7
SAT0312 Incidence of infections in clinical trials of tildrakizumab for moderate to severe chronic plaque psoriasis
https://doi.org/10.1136/annrheumdis-2018-eular.6730
THU0291 Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate to severe plaque psoriasis: data from 3 large randomised clinical trials
https://doi.org/10.1136/annrheumdis-2018-eular.6782
Documents that mention this clinical trial
AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis
https://doi.org/10.1136/annrheumdis-2018-eular.2983
Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis
https://doi.org/10.1007/s40262-019-00743-7
SAT0312 Incidence of infections in clinical trials of tildrakizumab for moderate to severe chronic plaque psoriasis
https://doi.org/10.1136/annrheumdis-2018-eular.6730
AB0544 EFFICACY AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME: 5-YEAR POOLED DATA FROM reSURFACE 1 AND reSURFACE 2
https://doi.org/10.1136/annrheumdis-2021-eular.1827
THU0291 Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate to severe plaque psoriasis: data from 3 large randomised clinical trials
https://doi.org/10.1136/annrheumdis-2018-eular.6782
Funding for this research was provided by:
Merck & Co., Inc.
Article History
First Online: 26 March 2019
Compliance with Ethical Standards
:
: This analysis was supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and conducted by Certara USA Inc.
: Petra Jauslin, Pooja Kulkarni, Hanbin Li, Suresh Vatakuti, and Thomas Kerbusch are employees of Certara USA, Inc. or its subsidiaries, who conducted analysis or provided consulting services for Merck & Co., Inc. Azher Hussain and Larissa Wenning are employees of Merck & Co., Inc., Kenilworth, NJ, USA, and hold stock and/or stock options in the company. Thomas Kerbusch is a former employee of Merck & Co., Inc., Kenilworth, NJ, USA, who was an employee of Certara USA, Inc. at the time of the analysis covered in this article.
: The studies used in this work were conducted in compliance with the Declaration of Helsinki, International Conference on Harmonization Guidelines for Good Clinical Practice, and applicable local regulations. The study protocols were approved by ethics committees of all participating centers.
: All patients provided written informed consent before study entry and the initiation of any study tests/procedures.